- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.05. | This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday | 19 | Benzinga.com | ||
| 12.05. | Boral Capital starts NeuroSense stock with Buy, $14 target | 12 | Investing.com | ||
| 07.05. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 140 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
| 09.04. | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 258 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen | |
| 08.04. | NeuroSense Therapeutics GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
| 07.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.04. | NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates | 133 | PR Newswire | Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
Ongoing partnership... ► Artikel lesen | |
| 07.04. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 27.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 25.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 25.03.2025 | 499 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.03.2025
Aktien
1 US50125G1094 KULR Technology Group... ► Artikel lesen | |
| 19.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.12.24 | NeuroSense Provides Business Update and Third Quarter 2024 Financial Results | 188 | PR Newswire | CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing... ► Artikel lesen | |
| 11.12.24 | NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC | 177 | PR Newswire | The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
... ► Artikel lesen | |
| 28.10.24 | NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission | 165 | PR Newswire | Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success
Parallel... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 0,920 | -20,96 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 54,50 | +1,87 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
| QIAGEN | 41,760 | -3,42 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,290 | +26,22 % | Novartis weighs deal for biotech Avidity Biosciences, FT reports | ||
| EVOTEC | 6,506 | -2,90 % | DAX-Check LIVE: Adidas, Alzchem, Evotec, KION, Krones, Mercedes, Porsche AG, Siemens Health. & Co | Das neue Zollabkommen zwischen der EU und den USA stand gestern erneut im Fokus der Börsianer. Trotz erwarteter Belastungen für die exportorientierte deutsche Wirtschaft sorgte die neu gewonnene Klarheit... ► Artikel lesen | |
| BIONTECH | 95,65 | -0,36 % | Wochenvorschau 32: August-Highlights: Von Biontech bis Munich Re - die Wirtschaftswoche | Die Woche vom 4. bis 8. August bringt Highlights von Biontech, Infineon und Siemens bis hin zu Allianz und Munich Re - begleitet von zentralen Konjunktursignalen weltweit.Die Woche vom 4. bis 8. August... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,615 | +10,94 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,515 | +0,06 % | Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition | ||
| AINOS | 3,300 | +43,48 % | Ainos, Inc.: Ainos Secures $2.1 Million Order With ASE Technology for First Deployment of AI Nose in Semiconductor Manufacturing Setting | First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial ApplicationsAinos Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan SAN... ► Artikel lesen | |
| NOVAVAX | 6,450 | +10,65 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 5,830 | -15,20 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
| VERA THERAPEUTICS | 19,250 | -6,73 % | Vera Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| RECURSION PHARMACEUTICALS | 5,480 | -0,63 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| MODERNA | 22,870 | -3,68 % | Moderna erhält EU-Zulassung für aktualisierten COVID-19-Impfstoff | Moderna hat von der Europäischen Kommission die Zulassung für die aktualisierte Version seines COVID-19-Impfstoffs Spikevax erhalten. Die neue Formulierung richtet sich gegen die SARS-CoV-2-Variante... ► Artikel lesen | |
| AMGEN | 244,70 | -5,72 % | Prognose-Schock vs. Prognose-Boost - Zalando, Fresenius, Beiersdorf, Qiagen, Super Micro, AMD, Amgen | Der DAX hat sich gestern erneut gut geschlagen und an die starke Performance vom Montag angeknüpft. Es gab zwar die eine oder andere Schwächephase. Trotzdem schloss der DAX 0,37 Prozent höher bei 23.846... ► Artikel lesen |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,090 (+8,65 %) liegt der Kurs bei 1,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.